Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Clinical trial NCT04322617 · RECRUITING
Trial details
- NCT number
- NCT04322617
- Sponsor
- Hunan Province Tumor Hospital
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-24
- Primary completion
- 2028-03-24
- Enrollment
- 1200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.